```text
Wiki Article
Abciximab (C7E3, 143653-53-6): A Research Reagent Overview
Abciximab, also identified as C7E3 or bearing the CAS number 143653-53-6, is a a valuable scientific substance extensively employed in cardiovascular research . This antibody fragment specifically targets the glycoprotein IIb/IIIa receptor on blood cells, blocking clot formation . As a result, it's commonly employed as a tool to analyze the pathways underlying clotting and to evaluate the performance of anticoagulant therapies. Supply is typically restricted to research settings.
```
The Abciximab Compound Research: Utilizing C7E3 and 143653-53-6 in Scientific Assessments
Ongoing studies into abciximab, a antiplatelet agent, frequently incorporates the monoclonal antibody C7E3 and the molecule identified as 143653-53-6. These reagents are instrumental for analyzing abciximab's mechanism of action, evaluating its therapeutic effect in different patient populations, and understanding potential predictors of treatment response. Further study leveraging these specific reagents is expected to provide valuable data for enhancing therapeutic strategies concerning cardiovascular conditions.
```text
C7E3 abciximab, also known as c7e3fragment, is a GPIIb/IIIa receptor antagonist widely utilized in scientific research. Its primary application lies in platelet aggregation studies, allowing investigators to probe the mechanisms underlying thrombosis and hemostasis. Researchers employ this agent to investigate the role of platelet activation in various disease models, including ischemia-reperfusion injury and inflammation. Beyond basic research, abciximab is increasingly used in developing novel antithrombotic therapies and evaluating their efficacy. Furthermore, studies exploring its potential to modulate vascular smooth muscle cell function and reduce intracranial bleeding are ongoing. The availability of c7e3 abciximab facilitates a deeper understanding of platelet-mediated processes and contributes to the advancement of translational medicine. }
```
```text
Analyzing Potential Opportunities with this Glycoprotein IIb/IIIa Inhibitor 143653-53-6 and C7E3
Recent studies indicate that the drug (identified as 143653-53-6) holds significant investigative promise, particularly when combined with C7E3 a C7E3 construct. Initial observations suggested that this combination might improve therapeutic outcomes in multiple heart-related conditions. Further exploration is centered on understanding the precise process of interaction between the antiplatelet medication and C7E3, involving assessment of thrombocyte aggregation and arterial protection.
- Ongoing study efforts aim to maximize administration strategies.
- Preclinical approaches are are being employed to more confirm the hypotheses.
- Clinical studies will be necessary to completely assess therapeutic effectiveness.
```
Abciximab (C7E3) for Research: Quality and Specifications (143653-53-6)
Researchers seeking abciximab for in vitro studies should carefully consider purity and precise characteristics. This product is typically offered as a lyophilized powder and detailed analytical information including verification by LC-MS, binding affinity assays, and bacterial endotoxin testing must be available. Ensure the supplier's CoA specifies acceptable limits for impurities and conforms to relevant quality assurance criteria .
Research-Grade ReoPro Details & Stock
Acquiring research-grade Abciximab, specifically referencing the antibody C7E3 and identified by the catalog number 143653-53-6, requires detailed consideration of its source . This glycoprotein is frequently utilized in in vitro experiments, particularly those involving platelet adhesion and thrombosis . Existing sources offer this material in varying amounts , typically ranging from milligram to substantial wholesale amounts . We advise reviewing the certificate of analysis to verify quality and suitability for your specific purpose. Moreover, check the expiration date before purchasing to maintain maximum effectiveness.
- Common Purity: >95%
- Storage Conditions: -20°C or controlled conditions
- Use : Platelet Aggregation Suppression Studies